FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET By Ogkologos - April 18, 2025 507 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR What to Know About 3 Common Misconceptions Around Food and Cancer... April 25, 2023 FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High... June 13, 2025 Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer August 29, 2018 EMA Recommends Extending Indications for Zanubrutinib to Include Treatment of Patients... November 2, 2023 Load more HOT NEWS Screening People at High Risk for Pancreatic Cancer May Help Them... Survivorship and Immune Checkpoint Inhibitors Alex Trebek Admits Undergoing Chemo For Stage 4 Pancreatic Cancer Has... What the Budget 2021 means for research
